Seedlings Life Science Ventures, LLC v. Pfizer Canada ULC

Seedlings Life Science Ventures, LLC v. Pfizer Canada ULC

The asserted claims are invalid because they are overly broad for failing to include essential elements disclosed as integral to the invention (a syringe carrier, a flat reverse syringe or collapsible bellows, and a shared latch locking mechanism); several asserted claims are also anticipated by prior art (US patents '965 and '369) and one claim is obvious; even if valid, the NGA EpiPen would not infringe the construed essential claim elements (EpiPen is not "flat", needle shield is not mounted to the housing, syringe positioned forward not rearward, and no actuation assembly as claimed).

Citation
2020 FC 1
Parties
Plaintiff / Defendant by Counterclaim: Seedlings Life Science Ventures, LLC; Defendant / Plaintiff by Counterclaim: Pfizer Canada ULC
Court
Federal Court
Jurisdiction
Canada
Judgment Date
2 January 2020
Procedural Posture
Patent Infringement / Validity / Judgment (trial)
Outcome
Plaintiff's action dismissed; Defendant's counterclaim allowed; asserted claims declared invalid; no infringement found.
Legal Topics
Claim Construction, Anticipation, Obviousness, Utility, Overbreadth, Insufficiency, Infringement, Remedies, Reasonable Royalty, Accounting of Profits
Source Language
English
Patent Intellectual Property Civil Litigation Claim Construction Anticipation Obviousness Utility Overbreadth +5 more

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Legal principles 6 Authorities cited 10 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Parties

Seedlings Life Science Ventures, LLC

Plaintiff / Defendant by Counterclaim

Pfizer Canada ULC

Defendant / Plaintiff by Counterclaim

Procedural Posture

Patent Infringement / Validity / Judgment (trial)

Legal Issues

  1. 1 Identity of person skilled in the art and common general knowledge
  2. 2 Proper construction of disputed claim terms (e.g. "flat housing", "within the housing", "retracted storage position", "movably mounted", "actuation assembly", "coupled to the power source")
  3. 3 Validity: anticipation, obviousness, utility, overbreadth, insufficiency

Ratio Decidendi

The asserted claims are invalid because they are overly broad for failing to include essential elements disclosed as integral to the invention (a syringe carrier, a flat reverse syringe or collapsible bellows, and a shared latch locking mechanism); several asserted claims are also anticipated by prior art (US patents '965 and '369) and one claim is obvious; even if valid, the NGA EpiPen would not infringe the construed essential claim elements (EpiPen is not "flat", needle shield is not mounted to the housing, syringe positioned forward not rearward, and no actuation assembly as claimed).

Court Disposition

Plaintiff's action dismissed; Defendant's counterclaim allowed; asserted claims declared invalid; no infringement found.

Orders

  • Plaintiff’s action is dismissed.
  • Defendant’s counter-claim is allowed.